74•应用研究•July2023,Vol.21,No.20GuideofChinaMedicine阿扎胞苷联合CAG方案治疗复发难治性急性髓系白血病的临床效果张娟柴俊月郑雯琦崔婷婷龚颉（北京市第六医院血液科，北京100007）【摘要】目的探讨阿扎胞苷联合CAG方案（阿糖胞苷、阿克拉霉素、重组人粒细胞集落刺激因子）治疗复发难治性急性髓系白血病的疗效及不良反应。方法选取2018年7月至2021年7月于北京市第六医院诊断为难治性及复发性急性髓系白血病患者68例，将阿扎胞苷联合CAG方案与CAG方案的治疗效果进行分组比较。结果阿扎胞苷联合CAG方案与CAG方案的总有效率（86.11%vs.65.63%）、缓解率（55.56%vs.37.5%）比较，差异有统计学意义（P＜0.05）；阿扎胞苷联合CAG方案化疗后中性粒细胞恢复时间及生活质量量表评分均优于CAG方案（P＜0.05）。两组不良反应发生率比较差异无统计学意义（P＞0.05）。结论阿扎胞苷联合CAG方案治疗复发难治性急性髓系白血病安全有效。【关键词】复发性难治性急性髓系白血病；阿扎胞苷；CAG方案；化学治疗；不良反应中图分类号：R733.7文献标识码：B文章编号：1671-8194（2023）20-0074-03AzacitidineCombinedwithCAGRegimenintheTreatmentofRelapsedandRefractoryAcuteMyeloidLeukemiaZHANGJuan,CHAIJunyue,ZHENGWenqi,CUITingting,GONGJie(DepartmentofHematology,theSixthHospitalofBeijing,Beijing100007,China)[Abstract]ObjectiveToinvestigatetheclinicalefficacyandadversereactionsofazacitidinecombinedwithCAG（cytarabine,aclarubicinandrecombinanthumangranulocytecolony-stimulatingfactor）regimeninthetreatmentofrelapsedandrefractoryacutemyeloidleukemia.MethodsFromJuly2018toJuly2021,68patientsdiagnosedwithrefractoryandrecurrentacutemyeloidleukemiaintheSixthHospitalofBeijingwereselected,andthetherapeuticeffectsofazacitidinecombinedwithCAGregimenwerecomparedingroups.ResultsComparedwiththetotalresponserate(86.11%vs.65.63%)andresponserate(55.56%vs.37.5%)ofazacitidineplusCAGregimen,thedifferenceswerestatisticallysignificant(P＜0.05),andtheneutrophilrecoverytimeandqualityoflifescalescoresafterchemotherapywithazacitidineplusCAGregimenwerebetterthanthoseofCAGregimen(P＜0.05).Therewasnosignificantdifferenceintheincidenceofadversereactionsbetweenthetwogroups(P＞0.05).ConclusionTherem...
